Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Dual Antibody Induction and De Novo Use of Everolimus Enable Low-Dose Tacrolimus with Early Corticosteroid Withdrawal in Simultaneous Pancreas-Kidney Transplantation.

Immunosuppressive regimen after simultaneous pancreas and kidney transplantation

Application of Combined Tacrolimus and Mycophenolate Mofetil in Simultaneous Kidney-Pancreas Transplantation

Short-term Follow-Up of 32 Simultaneous Pancreas-Kidney Transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Simultaneous Pancreas and Kidney Transplantation for Liver Transplant Recipients with Diabetes and Uremia.

Immunosuppressive Therapy in Pediatric Cadaveric Renal Transplantation

Impact of Everolimus Plus Calcineurin Inhibitor on Formation of Non-Hla Antibodies and Graft Outcomes in Kidney Transplant Recipients: 12-Month Results from the ATHENA Substudy

Clinical Analysis of 2520 Renal Transplantations in One Center

Simultaneous pancreas and kidney transplantation for liver transplant recipients with diabetes and uremia

Evaluating the Efficacy, Safety and Evolution of Renal Function with Early Initiation of Everolimus-Facilitated Tacrolimus Reduction in De Novo Liver Transplant Recipients: Study Protocol for a Randomized Controlled Trial

Early Initiation of Everolimus after Liver Transplantation: A Single-Center Experience.

Simultaneous Pancreas-Kidney Transplant Outcomes Stratified by Autoantibodies Status and Pretransplant Fasting C-peptide

Comparative Safety and Efficacy of Immunosuppressive Regimens Post-kidney Transplant: A Systematic Review

Tacrolimus versus Cyclosporine A for Simultaneous Pancreas-Kidney Transplant Recipients:A Meta-Analysis

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe

Simultaneous pancreas and kidney transplantation for 5 patients with diabetesplus end-stage renal disease

A Retrospective Monocenter Review of Simultaneous Pancreas-Kidney Transplantation with Bladder Drainage in China.

The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report